The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Production of pharmaceutical proteins by transgenic animals
Open accessAbstract
Proteins started being used as pharmaceuticals in the 1920s with insulin extracted from pig pancreas. In the early 1980s, human insulin was prepared in recombinant bacteria and it is now used by all patients suffering from diabetes. Several other proteins and particularly human growth hormone are also prepared from bacteria. This success was limited by the fact that bacteria cannot synthesize complex proteins such as monoclonal antibodies or coagulation blood factors which must be matured by post-translational modifications to be active or stable in vivo. These modifications include mainly folding, cleavage, subunit association, γ-carboxylation and glycosylation. They can be fully achieved only in mammalian cells which can be cultured in fermentors at an industrial scale or used in living animals. Several transgenic animal species can produce recombinant proteins but presently two systems started being implemented. The first is milk from farm transgenic mammals which has been studied for 20 years and which allowed a protein, human antithrombin III, to receive the agreement from EMEA (European Agency for the Evaluation of Medicinal Products) to be put on the market in 2006. The second system is chicken egg white which recently became more attractive after essential improvement of the methods used to generate transgenic birds. Two monoclonal antibodies and human interferon-β1a could be recovered from chicken egg white. A broad variety of recombinant proteins were produced experimentally by these systems and a few others. This includes monoclonal antibodies, vaccines, blood factors, hormones, growth factors, cytokines, enzymes, milk proteins, collagen, fibrinogen and others. Although these tools have not yet been optimized and are still being improved, a new era in the production of recombinant pharmaceutical proteins was initiated in 1987 and became a reality in 2006. In the present review, the efficiency of the different animal systems to produce pharmaceutical proteins are described and compared to others including plants and micro-organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Plant cell cultures for the production of recombinant proteins
Hellwig, S., Drossard, J., Twyman, R. M., & Fischer, R. (2004) · Nature Biotechnology · doi:10.1038/nbt1027 · Cited by 586
Germline transmission of genetically modified primordial germ cells
van de Lavoir, M.-C., Diamond, J. H., Leighton, P. A., Mather-Love, C., Heyer, B. S., Bradshaw, R., Kerchner, A., Hooi, L. T., Gessaro, T. M., Swanberg, S. E., et al. (2006) · Nature · doi:10.1038/nature04831 · Cited by 491
Giritch, A., Marillonnet, S., Engler, C., van Eldik, G., Botterman, J., Klimyuk, V., & Gleba, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606631103 · Cited by 419
Production of Complex Human Glycoproteins in Yeast
Hamilton, S. R., Bobrowicz, P., Bobrowicz, B., Davidson, R. C., Li, H., Mitchell, T., Nett, J. H., Rausch, S., Stadheim, T. A., Wischnewski, H., et al. (2003) · Science · doi:10.1126/science.1088166 · Cited by 407
Production of cattle lacking prion protein
Richt, J. A., Kasinathan, P., Hamir, A. N., Castilla, J., Sathiyaseelan, T., Vargas, F., Sathiyaseelan, J., Wu, H., Matsushita, H., Koster, J., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1271 · Cited by 341
Transgenic microalgae as green cell-factories
León-Bañares, R. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.11.003 · Cited by 329
Houdebine, L. M. (2000) · Transgenic Research · doi:10.1023/a:1008934912555 · Cited by 255
Self-citationProduction of human monoclonal antibody in eggs of chimeric chickens
Zhu, L., van de Lavoir, M.-C., Albanese, J., Beenhouwer, D. O., Cardarelli, P. M., Cuison, S., Deng, D. F., Deshpande, S., Diamond, J. H., Green, L., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1132 · Cited by 222
Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins
Weikert, S., Papac, D., Briggs, J., Cowfer, D., Tom, S., Gawlitzek, M., Lofgren, J., Mehta, S., Chisholm, V., Modi, N., et al. (1999) · Nature Biotechnology · doi:10.1038/15104 · Cited by 202
Cited by
Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding
Hickman, D. A., Pawlowski, C. L., Sekhon, U. D. S., Marks, J., & Gupta, A. S. (2018) · Advanced Materials · doi:10.1002/adma.201700859 · Cited by 583
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Expression of Recombinant Antibodies
Frenzel, A., Hust, M., & Schirrmann, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00217 · Cited by 353
Possibilities for an in vitro meat production system
Datar, I., & Betti, M. (2010) · Innovative Food Science & Emerging Technologies · doi:10.1016/j.ifset.2009.10.007 · Cited by 345
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Metadata
- Authors
- Houdebine, L.-M.
- Venue
- Comparative Immunology, Microbiology and Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 32
- Issue
- 2
- Pages
- 107-121
- ISSN
- 0147-9571 (ISSN-L)
- OpenAlex
- W2033978052
- Cited by
- 335
- References
- 23
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Production of pharmaceutical proteins by transgenic animals. https://app.cochat.ai/papers/10.1016/j.cimid.2007.11.005
- The paper
- Houdebine, L.-M. (2009). Production of pharmaceutical proteins by transgenic animals. Comparative Immunology, Microbiology and Infectious Diseases. https://doi.org/10.1016/j.cimid.2007.11.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.